AMGN is in a strong uptrend
+93
BearishSidewaysBullish
Why this reading
- Price is above its 50-day average ($419.38).
- Price is above its 200-day average ($371.19).
- The 50-day average is rising (+0.14%/day).
- 50-day average is above the 200-day (long-term structure is up).
- MACD momentum is improving and the MACD line is above zero.
- RSI 71 — strong momentum, but in overbought territory.
- Recent swings show higher highs and higher lows.
Price chart
Lower pane: RSI (14) with 70 and 30 marked. Arrows mark candlestick patterns.
Indicators
| Indicator | Value | Reading | What it means |
|---|---|---|---|
| Moving averages | Bullish stack | Bullish | 20-day $428.31, 50-day $419.38, 200-day $371.19 |
| RSI (14) | 71.0 | Bearish | Overbought — rallies this stretched often pause or pull back. |
| MACD (12,26,9) | +3.16 | Bullish | MACD is above its signal line. |
| Bollinger %B | 1.01 | Bullish | Closing above the upper band — strong push, but stretched. |
| Volatility (ATR 14) | $10.78 (2.3%) | Neutral | Typical daily volatility. |
| Volume vs 20d avg | 0.25× | Neutral | Light volume — the latest move has little participation. |
| 52-week range | 99% | Bullish | Low $280.95, high $467.71 |
Key levels
- $465.33Last close
- $374.91Support, 6 touches-19.4%
- $354.30Support, 9 touches-23.9%
- $332.97Support, 8 touches-28.4%
Recent candlestick patterns
- DojiNeutral
Open and close nearly equal — indecision between buyers and sellers.
- Shooting StarBearish
Long upper wick after an advance — buyers were rejected at higher prices.
- Bearish EngulfingBearish
A strong down candle fully covers the prior up candle's body after an advance.
- Three Black CrowsBearish
Three consecutive strong down candles, each closing lower — steady selling pressure.
Latest news
- Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on Cancerbenzinga
- FDA Reviews Amgen's Video for VECTIBIX Injectionfiscal.ai
- Amgen Announces Webcast for 2026 Third Quarter Financial Resultsfiscal.ai
- Regeneron and Amgen Narrow Scope of Eylea Biosimilar Lawsuitfiscal.ai
- Amgen Declares Fourth Quarter 2026 Dividendfiscal.ai